Roche's satralizumab cuts relapse risk in rare disease phase 3

In a phase 3 trial of its neuromyelitis optica spectrum disorder treatment satralizumab, Roche linked the anti-IL-6 antibody to a 55% reduction in the risk of relapse, showing the drug works but with scope to question how it will do against rivals.